Teitur Trophics

🚀 We’re Hiring: Programme Manager at Teitur Trophics! 🚀 Are you looking for an exciting opportunity in a growing biotech company? We’re searching for a Programme Manager to oversee our R&D programmes, track budgets, and support financial planning. This role offers flexibility and the chance to contribute to groundbreaking advancements in neurodegenerative disease treatments. 📍 Location: Aarhus, Denmark 📅 Application Deadline: March 31, 2025 (rolling applications – apply early!) Join us in shaping the future of biotech! Apply now: [email protected] #Hiring #ProgrammeManager #Biotech #CareerOpportunity #TeiturTrophics

💥 Teitur will be attending AD/PD 2025 in Vienna! Our CSO, Anders Dalby and our new CMO, will be at the AD/PD - Advances in Science & Therapy 2025 Conference in Vienna from April 1st – 5th 🧠 Anders Dalby will host a talk on our lead program, TT-P34, designed to halt disease progression of neurodegenerative disease including #Parkinson’s Disease and #Huntington’s Disease. As we prepare to enter the clinic this summer, we’re excited to share updates on this groundbreaking work! 🚀 If you’re attending, we’d love to connect! Reach out to set up a meeting and learn more about Teitur Trophics and our upcoming clinical studies. See you there! #Parkinson’s #Neurodegeneration #TeiturTrophics

Our CEO, Simon, will be attending #BIOEuropeSpring in Milan this month!💡 Don’t miss the chance to connect with him to learn more about our lead program, developing novel theraputics for treating and preventing neurodegenerative diseases 🧠

🚀 Exciting news! Our CDO, Edward Browne, will be at the CHDI Foundation's Annual Huntington’s Disease Therapeutics Conference in Palm Springs next week. He’ll be sharing updates on TT-P34, our lead program designed to halt disease progression in #Huntington’s Disease, as we prepare to enter the clinic this summer. If you’re attending, we’d love to connect! Reach out to set up a meeting and learn more about Teitur Trophics and our upcoming clinical studies. See you there! #HuntingtonsDisease #Neurodegeneration #TeiturTrophics

We are thrilled to announce that Teitur has received a Eurostars grant for the project: 𝘉𝘳𝘦𝘢𝘬𝘵𝘩𝘳𝘰𝘶𝘨𝘩 𝘙𝘦𝘨𝘦𝘯𝘦𝘳𝘢𝘵𝘪𝘷𝘦 𝘗𝘦𝘱𝘵𝘪𝘥𝘦 𝘛𝘩𝘦𝘳𝘢𝘱𝘺 𝘵𝘰 𝘊𝘶𝘳𝘦 𝘗𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘸𝘪𝘵𝘩 𝘚𝘦𝘯𝘴𝘰𝘳𝘪𝘯𝘦𝘶𝘳𝘢𝘭 𝘏𝘦𝘢𝘳𝘪𝘯𝘨 𝘓𝘰𝘴𝘴 (RE-HEAR). The € 2M project is a collaboration between Teitur Trophics, Cilcare and Hochschule für Life Sciences FHNW and aims to advance a groundbreaking peptide-based therapeutic uniquely targeting novel pathways of the SorCS2 receptor for Sensorineural Hearing Loss. Read more about it below.

We are happy to welcome Maya Tyssøy to our team. Maya will lead ESG initiatives, GDPR compliance & human resources at Teitur Trophics. With a solid educational and practical background in administration, HR Management and organizational deveopment Maya is going to support the focus on sustainability as well as evolvement and optimization of the Teitur operations.

Teitur Trophics will be attending the 43rd Annual #JPMorganHealthcareConference on January 13-16 in San Francisco, CA.   Our CEO Simon Mølgaard and Board Chair Charles Large will be attending, and we look forward to the opportunity to meet. Please get in touch if you want to learn more about our novel program TT-P34, for #Huntington’s Disease and #Parkinson’s Disease which will enter clinic this year.

Teitur is attending #HSG2024 in Cincinatti. If you are attending, we hope you will reach out to our CDO Edward Browne or CEO Simon Mølgaard to learn more about our unique program for treating patients suffering from #Huntinton’s Disease.

We are proud to have been nominated for EY Entrepreneur of The Year in the Life Sciences category. As Teitur Trophics is approaching Clinical studies, we are honoured to be recognised for the progress within the last year.

We are happy to welcome Mia Aaboe Jørgensen to our team. Mia will lead Project Management at Teitur Trophics supporting the alignment of the project teams and ensuring good communication between all internal and external parties. With a background in academic and biotech research managing preclinical in vivo studies, alongside management of project timelines for key deliverables, Mia will keep progression of our lead assets on track.